KRAS and non-small cell lung carcinoma: An integrative proteomic analysis suggested some prognosis-associated proteins and pathways in early stage NSCLC [9], while multi-omics clustering has also revealed that EGFR, KRAS, and STK11 are candidate drug targets for NSCLC [10].